AAPL vs ABBV: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and AbbVie Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
Apple Inc. · Technology
$308.63
+5.6% upside to fair value
Grade B
High Quality
VS
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
QuantHub Verdict
AAPL has more upside to fair value
(+5.6%).
AAPL trades at a lower forward P/E
(37.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
ABBV |
| Current Price |
$308.63 |
$261.07 |
| Fair Value Estimate |
$325.93 |
$264.30 |
| Upside to Fair Value |
+5.6%
|
+1.2%
|
| Market Cap |
$4,533.0B |
$461.3B |
| Forward P/E |
37.2x
|
128.0x
|
| EV / EBITDA |
28.6x
|
31.0x
|
| Price / Sales |
10.0x
|
7.3x
|
| Price / FCF |
35.1x
|
22.1x
|
| Revenue Growth YoY |
+16.6%
|
+12.4%
|
| Gross Margin |
47.9%
|
70.7%
|
| Operating Margin |
32.6%
|
27.6%
|
| Return on Equity |
146.7%
|
68.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.85%
|
4.52%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Apple Inc. is a leading technology company specializing in consumer electronics, software, and services, with a durable competitive moat driven by its integrated ecosystem of devices, operating systems, and services. The company benefits from strong brand loyalty, high margins with a gross margin of 47.9%, and consistent earnings growth, including a 19.4% increase in earnings in the most recent q…
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Accumulation Zones
| Metric |
AAPL |
ABBV |
| Zone Low |
$244.45 |
$198.23 |
| Zone High |
$277.04 |
$224.66 |
| In Buy Zone? |
No
|
No
|